Genome wide SNP analysis in Parkinson's disease

$712,295ZIAFY2021AGNIH

National Institute On Aging

Investigators

Linked publications & trials

Paper 39283294 Paper 38943243 Paper 38940474 Paper 38889728 Paper 38557965 Paper 38390630 Paper 38191580 Paper 37348876 Paper 34275906 Paper 33987465 Paper 33960523 Paper 33944973 Paper 33901317 Paper 33513272 Paper 33497488 Paper 33307186 Paper 33111402 Paper 33002231 Paper 32873436 Paper 32601912 Paper 31958187 Paper 31755958 Paper 31404238 Paper 31234232 Paper 31123700 Paper 30957308 Paper 30675927 Paper 29536161 Paper 29505953 Paper 29398121 Paper 29311653 Paper 29030452 Paper 28892059 Paper 28631854 Paper 28609445 Paper 28604798 Paper 28602509 Paper 28594127 Paper 28558379 Paper 28264768 Paper 28256260 Paper 27987235 Paper 27492190 Paper 27393345 Paper 27349602 Paper 27312774 Paper 27311081 Paper 27258413 Paper 27241037 Paper 27090875 Paper 27076492 Paper 27021906 Paper 27017469 Paper 26643944 Paper 26389967 Paper 26378242 Paper 26271532 Paper 26268663 Paper 26067110 Paper 26050140 Paper 26022768 Paper 25814571 Paper 25778492 Paper 25773351 Paper 25728432 Paper 25687905 Paper 25687773 Paper 25631608 Paper 25603768 Paper 25444595 Paper 25174650 Paper 25064009 Paper 24993959 Paper 24439955 Paper 24080174 Paper 24057672 Paper 23979011 Paper 23967090 Paper 23921447 Paper 23645593 Paper 23546887 Paper 23408064 Paper 23390085 Paper 23389780 Paper 22959728 Paper 22911860 Paper 22892372 Paper 22777693 Paper 22763023 Paper 22721568 Paper 22438815 Paper 22427796 Paper 21738488 Paper 21651510 Paper 21292315 Paper 21248740 Paper 21072532 Paper 20955927 Paper 20813421 Paper 20226542

Abstract

The genetic contribution to a number of neurological disorders is thought to be complex in nature, disease risk being driven by a combination of risk alleles commonly present in the human genome. Over the last 10 years we have invested considerable time and resources in applying genome wide association methods to determine the genetic basis of Parkinson disease. We formed the International Parkinson's Disease Genomics Consortium to facilitate international collaboration amongst leading Parkinson disease research groups focused on understanding the genetic basis of this disease. We extended the genome wide association in PD to include a cohort of approximately 60,000 disease cases or disease-related cases, and 1.5 million controls. This work revealed 90 risk loci for disease, has redefined the heritable component of Parkinson disease, has identified critical tissue and cellular context for genetic risk, and revealed co-morbid conditions. We have recently formed the Global Parkinsons Genetics Program (GP2) through the Aligning Science Across Parkinsons (ASAP) initiative. GP2 plans to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinsons disease. GP2 aims to increase the number of identified genes, disease-causing mutations, and risk loci for both monogenic and complex PD. We will also prioritize individuals from underrepresented backgrounds in these efforts. A subset of cases will undergo whole-genome sequencing to elucidate genetics contributing to monogenic PD, or long-read DNA sequencing to sequence challenging genomic regions.

View original record on NIH RePORTER →